In this issue:
Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients
Outcomes in BRAF-mutant advanced melanoma treated with first-line anti-PD1 monotherapies vs BRAF/MEK inhibitors
Increased serum CCL26 is a potential biomarker for the effectiveness of anti-PD1 in advanced melanoma
PD1 inhibitors might limit the development of brain metastases in advanced melanoma
Cost-utility analysis of frontline BRAF testing–guided treatment for advanced melanoma in the era of immunotherapies
Association of CD68+ and CD163+ macrophages with prognosis and functional changes in advanced melanoma
Nivolumab and ipilimumab in metastatic uveal melanoma
Characterisation of GNAQ and GNA11 mutant nonuveal melanoma
Role of SLNB in melanoma patients with LR or IT metastasis
Clinical and molecular features of subungual melanomas
Please login below to download this issue (PDF)